Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 26

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine

Simon, David K., Wu, Cai, Tilley, Barbara C., Wills, Anne-Marie, Aminoff, Michael J., Bainbridge, Jacquelyn, Hauser, Robert A., Schneider, Jay S., Sharma, Saloni, Singer, Carlos, Tanner, Caroline M., Truong, Daniel, Wong, Pei Shieen·2015·Clinical Neuropharmacology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/wnf.0000000000000102

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 15

  1. Fernandez-Duenas, 2014, Uncovering caffeines adenosine A2A receptor inverse agonism in experimental parkinsonism., ACS Chem Biol, 9, 2496, 10.1021/cb5005383 · DOI
  2. Kachroo, 2012, Adenosine A2A receptor gene disruption protects in an -synuclein model of Parkinsons disease., Ann Neurol, 71, 278, 10.1002/ana.22630 · DOI
  3. 2006, A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease., Neurology, 66, 664, 10.1212/01.wnl.0000201252.57661.e1 · DOI · Paper page
  4. 2007, A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease., Neurology, 68, 20, 10.1212/01.wnl.0000250355.28474.8e · DOI
  5. Simon, 2008, Caffeine and progression of Parkinson disease., Clin Neuropharmacol, 31, 189, 10.1097/WNF.0b013e31815a3f03 · DOI
  6. Morelli, 2010, Pathophysiological roles for purines: adenosine, caffeine and urate., Prog Brain Res, 183, 183, 10.1016/S0079-6123(10)83010-9 · DOI
  7. Bentley, 2014, Rare POLG1 CAG variants do not influence Parkinsons disease or polymerase gamma function., Mitochondrion, 15, 65, 10.1016/j.mito.2014.01.004 · DOI
  8. McGuine, 2001, Creatine supplementation in high school football players., Clin J Sport Med, 11, 247, 10.1097/00042752-200110000-00007 · DOI · Paper page
  9. Postuma, 2012, Caffeine for treatment of Parkinson disease: a randomized controlled trial., Neurology, 79, 651, 10.1212/WNL.0b013e318263570d · DOI · Paper page
  10. Hespel, 2002, Opposite actions of caffeine and creatine on muscle relaxation time in humans., J Appl Physiol, 92, 513, 10.1152/japplphysiol.00255.2001 · DOI · Paper page
  11. Vandenberghe, 1996, Caffeine counteracts the ergogenic action of muscle creatine loading., J Appl Physiol, 80, 452, 10.1152/jappl.1996.80.2.452 · DOI · Paper page
  12. Choi, 2007, Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey., Arthritis Rheum, 57, 816, 10.1002/art.22762 · DOI
  13. Swanson, 1994, Caffeine and nicotine: a review of their joint use and possible interactive effects in tobacco withdrawal., Addict Behav, 19, 229, 10.1016/0306-4603(94)90027-2 · DOI
  14. Tanner, 2009, Occupation and risk of parkinsonism: a multicenter case-control study., Arch Neurol, 66, 1106, 10.1001/archneurol.2009.195 · DOI · Paper page
  15. Addicott, 2009, Methodological considerations for the quantification of self-reported caffeine use., Psychopharmacology (Berl), 203, 571, 10.1007/s00213-008-1403-5 · DOI

Cited by

See all 26

Metadata

Authors
Simon, D. K., Wu, C., Tilley, B. C., Wills, A.-M., Aminoff, M. J., Bainbridge, J., Hauser, R. A., Schneider, J. S., Sharma, S., Singer, C., Tanner, C. M., Truong, D., & Wong, P. S.
Venue
Clinical Neuropharmacology
Published
2015-09
Volume
38
Issue
5
Pages
163-169
ISSN
0362-5664
Cited by
26
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.